Literature DB >> 12150967

Loss of placental growth factor protects mice against vascular permeability in pathological conditions.

Aernout Luttun1, Koen Brusselmans, Hideharu Fukao, Marc Tjwa, Shigeru Ueshima, Jean-Marc Herbert, Osamu Matsuo, Désiré Collen, Peter Carmeliet, Lieve Moons.   

Abstract

Vascular leakage contributes to numerous disorders but only a limited number of molecules have been demonstrated to modulate permeability of the vessel wall. The vascular endothelial growth factor (VEGF) is a potent inducer of vascular leakage. Previous studies demonstrated that exogenous administration of placental growth factor (PlGF), a homologue of VEGF, stimulates vascular permeability but the role of endogenous PlGF in plasma extravasation during pathological conditions remains unknown. We recently generated PlGF deficient (PlGF(-/-)) mice and demonstrated that loss of PlGF impaired pathological angiogenesis by attenuating the response to VEGF. Here, we demonstrate that absence of PlGF reduces vascular leakage induced by skin wounding, allergens, and neurogenic inflammation. These findings suggest that inhibition of PlGF might be an attractive tool to reduce vascular leakage in various diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12150967     DOI: 10.1016/s0006-291x(02)00677-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  Vascular permeability, vascular hyperpermeability and angiogenesis.

Authors:  Janice A Nagy; Laura Benjamin; Huiyan Zeng; Ann M Dvorak; Harold F Dvorak
Journal:  Angiogenesis       Date:  2008-02-22       Impact factor: 9.596

2.  Serum protein N-glycan alterations of diethylnitrosamine-induced hepatocellular carcinoma mice and their evolution after inhibition of the placental growth factor.

Authors:  Bram Blomme; Femke Heindryckx; Jean Marie Stassen; Anja Geerts; Isabelle Colle; Hans Van Vlierberghe
Journal:  Mol Cell Biochem       Date:  2012-09-24       Impact factor: 3.396

Review 3.  The role of VEGF in normal and neoplastic hematopoiesis.

Authors:  Hans-Peter Gerber; Napoleone Ferrara
Journal:  J Mol Med (Berl)       Date:  2002-12-14       Impact factor: 4.599

4.  Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth.

Authors:  Xiaojuan Yang; Yin Zhang; Yunlong Yang; Sharon Lim; Ziquan Cao; Janusz Rak; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-05       Impact factor: 11.205

5.  Circulating angiogenic and inflammatory cytokine responses to acute aerobic exercise in trained and sedentary young men.

Authors:  Rian Q Landers-Ramos; Nathan T Jenkins; Espen E Spangenburg; James M Hagberg; Steven J Prior
Journal:  Eur J Appl Physiol       Date:  2014-03-19       Impact factor: 3.078

Review 6.  An unexpected tail of VEGF and PlGF in pre-eclampsia.

Authors:  David O Bates
Journal:  Biochem Soc Trans       Date:  2011-12       Impact factor: 5.407

Review 7.  Life is a pattern: vascular assembly within the embryo.

Authors:  Jennifer Heinke; Cam Patterson; Martin Moser
Journal:  Front Biosci (Elite Ed)       Date:  2012-01-01

8.  Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability.

Authors:  Jun Cai; Lin Wu; Xiaoping Qi; Lynn Shaw; Sergio Li Calzi; Sergio Caballero; Wen G Jiang; Stanley A Vinores; David Antonetti; Asif Ahmed; Maria B Grant; Michael E Boulton
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

9.  Elevated levels of placental growth factor represent an adaptive host response in sepsis.

Authors:  Kiichiro Yano; Yoshiaki Okada; Guido Beldi; Shou-Ching Shih; Natalya Bodyak; Hitomi Okada; Peter M Kang; William Luscinskas; Simon C Robson; Peter Carmeliet; S Ananth Karumanchi; William C Aird
Journal:  J Exp Med       Date:  2008-10-13       Impact factor: 14.307

10.  Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.

Authors:  D Checkley; J J Tessier; J Kendrew; J C Waterton; S R Wedge
Journal:  Br J Cancer       Date:  2003-11-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.